Quadrant Capital Group’s Surmodics SRDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-548
| Closed | -$16.4K | – | 2783 |
|
|
2025
Q3 | $16.4K | Buy |
+548
| New | +$18.3K | ﹤0.01% | 2011 |
|
|
2025
Q2 | – | Sell |
-61
| Closed | -$1.86K | – | 2455 |
|
|
2025
Q1 | $1.86K | Buy |
+61
| New | +$2.05K | ﹤0.01% | 2523 |
|
|
2023
Q1 | – | Sell |
-837
| Closed | -$28.6K | – | 2785 |
|
|
2022
Q4 | $28.6K | Buy |
837
+168
| +25% | +$5.63K | ﹤0.01% | 1481 |
|
|
2022
Q3 | $20K | Buy |
669
+272
| +69% | +$9.33K | ﹤0.01% | 1545 |
|
|
2022
Q2 | $15K | Buy |
397
+375
| +1,705% | +$14.5K | ﹤0.01% | 1450 |
|
|
2022
Q1 | $1K | Hold |
22
| – | – | ﹤0.01% | 2392 |
|
|
2021
Q4 | $1K | Sell |
22
-21
| -49% | -$1.06K | ﹤0.01% | 2403 |
|
|
2021
Q3 | $2K | Buy |
43
+17
| +65% | +$944 | ﹤0.01% | 2194 |
|
|
2021
Q2 | $1K | Buy |
26
+4
| +18% | +$219 | ﹤0.01% | 2321 |
|
|
2021
Q1 | $1K | Hold |
22
| – | – | ﹤0.01% | 2291 |
|
|
2020
Q4 | $1K | Hold |
22
| – | – | ﹤0.01% | 2191 |
|
|
2020
Q3 | $1K | Hold |
22
| – | – | ﹤0.01% | 2049 |
|
|
2020
Q2 | $1K | Hold |
22
| – | – | ﹤0.01% | 2127 |
|
|
2020
Q1 | $1K | Buy |
+22
| New | +$794 | ﹤0.01% | 2039 |
|
Other funds holding SRDX
Quadrant Capital Group's SRDX Position: Q4 2025 in Review
Quadrant Capital Group sold out of Surmodics (SRDX) in Q4 2025, closing a stake of 548 shares — an estimated $16.4K sold.
Quadrant Capital Group first reported a position in SRDX in Q1 2020 and held it in 14 quarters. The position peaked at $28.6K in Q4 2022. 1 fund tracked by Wall St. Rank holds SRDX as of Q4 2025.
- Quadrant Capital Group reported no remaining Surmodics position as of Q4 2025 after selling out during the quarter.
- Quadrant Capital Group sold 548 Surmodics shares in Q4 2025, an estimated $16.4K.
- Quadrant Capital Group first reported a position in Surmodics in Q1 2020 and held it in 14 quarters.
- Quadrant Capital Group's Surmodics position peaked at $28.6K in Q4 2022.
- 1 fund tracked by Wall St. Rank held Surmodics as of Q4 2025.
Based on Quadrant Capital Group's 13F filing for Q4 2025, filed 13 Feb 2026.